Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

3(50.0%)

N/A

2(33.3%)

Phase 3

1(16.7%)

6Total

Phase 1(3)

N/A(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06258447Not ApplicableRecruiting

CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With Reduced Ejection Fraction

Role: lead

NCT05491681Phase 1Withdrawn

AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial

Role: lead

NCT03455725Not ApplicableActive Not Recruiting

CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial

Role: lead

NCT05925608Phase 1Active Not Recruiting

Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells

Role: lead

NCT02438306Phase 3Completed

CardiAMP™ Cell Therapy for Heart Failure Trial

Role: lead

NCT00507468Phase 1Completed

Autologous Bone Marrow Transplanted Via Transendocardial Catheter to Chronic Myocardial Infarct Border Zone

Role: lead

All 6 trials loaded